SK Bioscience’s new coronavirus infection (COVID-19) vaccine ‘Skycobi One Multi-Zoo (hereinfollowing referred to as SkyCoby One)’ received national shipment approval for the first time.
This has crossed the last gateway for market supply, and the industry’s attention is focused on the scale of Skycobi One’s inoculation at home and abroad.
On the 26th, the Ministry of Food and Drug Safety (Director Yoo-kyung Oh) announced that SK Bioscience had approved the shipment of 610,000 units of Skycobi One developed and manufactured in Korea.
The national shipping approval is a system in which the national government comprehensively evaluates the test results for each manufacturing unit (lot) and the manufacturer’s manufacturing and test results to confirm the quality once more before the vaccine is distributed on the market.
The Ministry of Food and Drug Safety (MFDS) conducted a verification test on 610,000 batches of Skycobi One and, following reviewing the manufacturer’s manufacturing and testing data, determined that it was suitable for the approved quality and decided to approve the national shipment.
The Ministry of Food and Drug Safety said, “We will continue to do our best to provide a stable supply of quality-secured vaccines by rapidly and thoroughly verifying the COVID-19 vaccine.”
